E
Eran Goldin
Researcher at Shaare Zedek Medical Center
Publications - 124
Citations - 5032
Eran Goldin is an academic researcher from Shaare Zedek Medical Center. The author has contributed to research in topics: Inflammatory bowel disease & Colitis. The author has an hindex of 30, co-authored 117 publications receiving 4205 citations. Previous affiliations of Eran Goldin include Hadassah Medical Center.
Papers
More filters
Journal ArticleDOI
Natalizumab for Active Crohn's Disease
Subrata Ghosh,Eran Goldin,Fiona H. Gordon,Helmut Malchow,Jørgen Rask-Madsen,Paul Rutgeerts,Petr Vyhnálek,Zdena Zádorová,Tanya Palmer,Stephen Donoghue +9 more
TL;DR: Treatment with the selective adhesion-molecule inhibitor natalizumab increased the rates of clinical remission and response, improved the quality of life and C-reactive protein levels, and was well tolerated in patients with active Crohn's disease.
Journal ArticleDOI
Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial.
Julián Panés,Damián García-Olmo,Gert Van Assche,Jean-Frederic Colombel,Walter Reinisch,Walter Reinisch,Daniel C. Baumgart,Axel Dignass,Maria Nachury,Marc Ferrante,Lili Kazemi-Shirazi,Jean Charles Grimaud,Fernando de la Portilla,Eran Goldin,Marie Paule Richard,Anne Leselbaum,Silvio Danese +16 more
TL;DR: Cx601 is an effective and safe treatment for complex perianal fistulas in patients with Crohn's disease who did not respond to conventional or biological treatments, or both.
Journal ArticleDOI
Long-term Efficacy and Safety of Stem Cell Therapy (Cx601) for Complex Perianal Fistulas in Patients With Crohn’s Disease
Julián Panés,Damián García-Olmo,Gert Van Assche,Jean-Frederic Colombel,Walter Reinisch,Walter Reinisch,Daniel C. Baumgart,Axel Dignass,Maria Nachury,Marc Ferrante,Lili Kazemi-Shirazi,Jean Charles Grimaud,Fernando de la Portilla,Eran Goldin,Marie Paule Richard,Mary Carmen Diez,Ignacio Tagarro,Anne Leselbaum,Silvio Danese,Jean Fred Colombel,Anton Stift,Jörg Tschmelitsch,Karl Mrak,Herbert Tilg,Irmgard Kroberger,André D'Hoore,Danny De Looze,Filip Baert,Paul Pattyn,Philippe Zerbib,Frank Zerbib,Stephanie Viennot,Jean-Louis Dupas,Pierre-Charles Orsoni,Xavier Hébuterne,Amine Rahili,Matthieu Allez,Yves Panis,Max Reinshagen,Roland Scherer,Andreas Sturm,Wolfgang Kruis,Daniel-Simon Duek,Matti Waterman,Adi Lahat-Zok,Oded Zmora,Hagit Tulchinsky,Y. Edden,Antonino Spinelli,Vito Annese,Imerio Angriman,Gabriele Riegler,Francesco Selvaggi,Bas Oldenburg,Lennard Gilissen,Gust Van Montfort,Mark Löwenberg,Adrianus Willem Bemelman,Raúl Almenara,María Dolores Martín Arranz,Mariano García-Arranz,Javier P. Gisbert,Rosana Palasí,Carlos Taxonera Samso,José Manuel Herrera Justiniano,Ricardo Rada,Mª Teresa Butrón,Daniel Carpio López,Antonio López-Sanromán,Joaquín Hinojosa de Val,Amparo Solana,F. Xavier González Argenté,Carlos Pastor,Héctor Guadalajara +73 more
TL;DR: In a phase 3 trial of patients with Crohn's disease and treatment-refractory complex perianal fistulas, Cx601 is found to be safe and effective in closing external openings, compared with placebo, after 1 year.
Journal ArticleDOI
Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel disease
TL;DR: ASA and pANCA may predict development of inflammatory bowel disease years before the disease is clinically diagnosed and measurements of the average time from the presence of ASCA to diagnosis may be even longer.
Journal ArticleDOI
Mutant KRAS is a druggable target for pancreatic cancer
Elina Zorde Khvalevsky,Racheli Gabai,Itzhak Haim Rachmut,Elad Horwitz,Zivia Brunschwig,Ariel Orbach,Adva Shemi,Talia Golan,Abraham J. Domb,Eylon Yavin,Hilla Giladi,Ludmila Rivkin,Alina Simerzin,Rami Eliakim,Abed Khalaileh,Ayala Hubert,Maor Lahav,Yael Kopelman,Eran Goldin,A Dancour,Yael Hants,Sagit Arbel-Alon,Rinat Abramovitch,Amotz Shemi,Eithan Galun +24 more
TL;DR: A reproducible and safe delivery platform based on a miniature biodegradable polymeric matrix, for the controlled and prolonged delivery of siRNA that overcomes the major obstacles of toxicity and organ accessibility is reported.